Navigation Links
Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Date:6/26/2008

mean TST during the first third of the night improved by 45.2 minutes in the 20mg group (p<.001), by 40.1 minutes in the 50mg group (p<.01), and by 30.6 minutes in the placebo group. All statistical comparisons are between tasimelteon dose versus placebo.

-- Mean WASO during the first third of the night at baseline (before drug treatment) was 20.8 minutes in the 20mg group, 21.3 minutes in the 50mg group, and 21.3 minutes in the placebo group. On Nights 1 and 8 of treatment, mean WASO during the first third of the night improved by 2.3 minutes in the 20mg group (p<.01), and by 1.8 minutes in the 50mg group (p<.05), but worsened by 3.1 minutes in the placebo group. On Nights 22 and 29 of treatment, mean WASO during the first third of the night improved by 3.1 minutes in the 20mg group (nss), by 1.8 minutes in the 50mg group (nss) and by 0.6 minutes in the placebo group. All statistical comparisons are between tasimelteon dose versus placebo.

These results reveal that tasimelteon was able to achieve a number of statistically significant improvements on sleep maintenance parameters during the portion of the night in which the patient population studied suffered the greatest impairment. These data are consistent with data from the prior Phase III study (VP-VEC-162-3101), in which 20mg and 50mg of tasimelteon significantly improved LPS (by 21.5 to 26.3 minutes compared to placebo), WASO (by 24.7 to 33.7 minutes compared to placebo), and TST (by 33.7 to 47.9 minutes compared to placebo) in a model of transient insomnia. Taken together, the results of both of these studies demonstrate the versatility of tasimelteon to treat the symptoms of insomnia acutely and chronically both in a model of transient insomnia and in patients with chronic primary insomnia.

"These results suggest that circadian misalignment may play an important role in the pathophysiology of chronic primary insomnia in many patients, especially those who have difficulty falling asleep,"
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013 Hemoglobin A1C levels ... with Type 2 diabetes, while modest improvements in ... outcomes and can lead to substantial healthcare cost ... International Society for Pharmacoeconomics and Outcomes Research (ISPOR) ... studies, sponsored by Valeritas, makers of the V-Go ...
(Date:5/22/2013)... , May 22, 2013  Generex Biotechnology Corporation ... demonstrating the superiority of the AE37 breast cancer vaccine ... ( www.antigenexpress.com ). The presentations will be made at ... Oncology (ASCO) to be held in Chicago ... The presentation entitled " Booster inoculations of ...
(Date:5/22/2013)...  Flagship Ventures, a leading venture capital and ... today announced the appointment of Stephane ... this role, Mr. Bancel will provide strategic counsel ... addition to working closely with companies in the ... and Chief Executive Officer of Moderna Therapeutics, a ...
Breaking Medicine Technology:Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3
(Date:5/22/2013)... Angeles, CA (PRWEB) May 22, 2013 Many ... a great deal of pain for a patient if left ... that their pain could be easily fixed through occlusal adjustment. ... teeth, or neck and back pain should have their dentist ... can change the bite and can lead to problems if ...
(Date:5/22/2013)... is available in German . ... Research Foundation) is establishing 11 new Research Training Groups ... decision was made by the relevant Grants Committee in ... awarded to the new programmes for an initial period ... the 11 new Research Training Groups, the Grants Committee ...
(Date:5/22/2013)... Hopkins researchers have developed new guidelines the first ... amount of blood ordered for surgical patients. The recommendations, ... The Johns Hopkins Hospital (JHH), can potentially save the ... patient safety, researchers say. , A report on the ... online in the journal Anesthesiology , suggests millions ...
(Date:5/22/2013)... Ethos Spa Skin and Laser Center , has ... lifestyle of the modern man and woman. All customers have ... whether it is for an anniversary or birthday present, a ... , Clients should know that they have a wide selection ... the Ethos Spa’s website, ranging from abstract artistic drawings to ...
(Date:5/22/2013)... May 22, 2013 Beginning Aug. 22, ... the Conrad Foundation’s Spirit of Innovation Challenge . ... plan competition, free and open to students ages 13 ... Spirit of Innovation Challenge celebrates the life and entrepreneurial ... on the Moon. The program challenges teens to work ...
Breaking Medicine News(10 mins):Health News:Dr. Martin N. Gorman: Make Headaches, Sensitive Teeth and Neck or Back Pain a Thing of the Past 2Health News:DFG establishes 11 new research training groups 2Health News:DFG establishes 11 new research training groups 3Health News:DFG establishes 11 new research training groups 4Health News:DFG establishes 11 new research training groups 5Health News:Johns Hopkins rewrites obsolete blood-ordering rules 2Health News:Johns Hopkins rewrites obsolete blood-ordering rules 3Health News:Ethos Spa Skin And Laser Center Has Launched Their Customizable Gift Certificates 2Health News:Conrad Foundation Announces 2013-2014 Spirit of Innovation Challenge Launch Date 2
... , FRIDAY, Jan. 20 (HealthDay News) -- Rapid ... with an increased risk of asthma symptoms in preschool children, ... infancy might be a critical period for the development of ... Netherlands. They examined data collected from 5,125 children who ...
... non-intubated,patients may be an effective strategy for bridging patients ... Germany. "As waiting times for donor organs continue ... for patients with end-stage lung disease awaiting transplantation," said ... Hannover Medical School in Hannover, Germany. "Our study shows ...
... Shortages of key drugs used to fight infections represent ... risk, according to a review published in Clinical ... anti-infective shortages can substantially alter clinical care and may ... development of new anti-infectives has slowed and the prevalence ...
... , THURSDAY, Jan. 19 (HealthDay News) -- Allowing homeless ... were provided with housing actually decreased their heavy drinking by ... found. The study, published in the Jan. 19 issue ... included residents of a program called project-based Housing First, which ...
... aggressive and spread they are the most deadly. Unfortunately, ... A new imaging platform developed by Lawson Health Research ... insight into just that - the exact moment when ... E-cadherin, are important for the maintenance of normal tissue ...
... With a growing need for family-friendly workplace policies, ... Women & Families, with support from the Rockefeller Foundation, ... to positive economic outcomes for working families, businesses and ... for Women and Work at Rutgers, the State University ...
Cached Medicine News:Health News:Rapid Infant Growth Linked to Asthma in Study 2Health News:Extracorporeal membrane oxygenation as a bridge to lung transplantation 2Health News:Anti-infective drug shortages pose threat to public health and patient care 2Health News:Alcohol OK in Housing for Formerly Homeless, Study Says 2Health News:Lawson researchers engineer a switch to tame aggressive cancers 2Health News:Rutgers study finds paid family leave leads to positive economic outcomes 2Health News:Rutgers study finds paid family leave leads to positive economic outcomes 3
... Administration Control System, provides the healthcare ... are administering the correct medication to ... bar coded patient bracelet and a ... of the hospital's pharmacy system to ...
... administration, any error is one you simply ... the Dynamic Hospital AdministratOR. This powerful application ... suitable for hospitals of all sizes. It ... as a fully-integrated component of existing systems. ...
... that support the nursing process. The caregiver ... I&O information at the point of collection ... This design supports compliance with documentation requirements., ... at the nursing station, wCareAssist™ is right ...
... critical information to the patient's unique bar-coded identifier for accurate, easy recording of tests, diagnosis and care. ... ... ... Patient LinkUp™ Enterprise (PLUE) ...
Medicine Products: